【how to measure for cock cage】Cardinal Health (CAH) Beats on Earnings & Revenues in Q4
Cardinal Health Inc.
CAH is how to measure for cock cagea healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2017 earnings report which has just released. You can see
the complete list of today’s Zacks #1 Rank
(Strong Buy)
stocks here
. We have highlighted some of the key details from the just-released announcement below:
Earnings:
Cardinal Health’s adjusted earnings rose 14.9% on a year-over-year basis to $1.31 per share. It also outpaced the Zacks Consensus Estimate of $1.24.
Revenues:
Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Cardinal Health, Inc. Price and EPS Surprise
Cardinal Health, Inc. Price and EPS Surprise | Cardinal Health, Inc. Quote
Key Stats:
Pharmaceutical revenues surged 5% to $29.6 billion while revenues from Medical segment increased 6% to $3.4 billion in the quarter.
Pharmaceutical segment revenues increased due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers. Higher contributions from net new and existing customers and solid performance in the post-acute segment were primarily responsible for the growth in Medical segment revenues.
The company expects adjusted earnings for fiscal 2018 in the range of $4.85 to $5.10 per share.
Check back later for our full write up on this Cardinal Health earnings report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
View comments
(责任编辑:Encyclopedia)
- Which Consumer Staples Stock Will Grow The Most By 2025?
- Why Is Maximus (MMS) Down 12.8% Since Last Earnings Report?
- Freedom Trail and Black Heritage Trail Bring History Into Homes Near and Far
- Culp: Q2 Earnings Insights
- German Court Issues a Dangerous Verdict for the ECB
- Is VirnetX Holding Corporation (VHC) A Good Stock To Buy?
- Evotec to Attend Upcoming Investor Conferences
- SHAREHOLDER ALERT: CLAIMSFILER REMINDS FSCT, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
- Mike Bloomberg thinks a gun-control pitch works … in Texas
- A Sliding Share Price Has Us Looking At Malibu Boats, Inc.'s (NASDAQ:MBUU) P/E Ratio
- Integrated Passive Devices Market revenue to cross USD 2 Billion by 2026: Global Market Insights, Inc.
- SponsorsOne Assembles Management Dream Team For Craft Alcohol Product Development, Branding, Marketing, Sales and Distribution
- Are Investors Undervaluing American Outdoor Brands (AOBC) Right Now?
- Company News for Mar 10, 2020
- Newmont (NEM) in Focus: Stock Moves 6.2% Higher
- Vior Completes Till Sampling and Expands Its Land Position at Skyfall, Abitibi, Quebec
- SCOR successfully sponsors a new catastrophe bond, Atlas Capital Reinsurance 2020 DAC
- Thermon Group Holdings, Inc. to Host Earnings Call
- Don't Let China Control Your Networks, U.S. Envoy Tells Europe
- Despite Its High P/E Ratio, Is Ovzon AB (publ) (STO:OVZON) Still Undervalued?